Skip to content
Screener

Kymera Therapeutics KYMR Q1 2026 earnings

Reported April 30, 2026 · Before market open

Revenue$34.4MBeat by $26.1M
EPS-$0.71Beat by $0.18
Revenue estimate$8.3M
EPS estimate-$0.89

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$3.3M
EPS estimate-$1.25

Financials

Q1 2026

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$6.8B+283%
Enterprise value$6.74B+280%
P/S132.1×+102×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

FAQ

When did Kymera Therapeutics report Q1 2026 earnings?
Kymera Therapeutics (KYMR) reported Q1 2026 earnings on April 30, 2026 before market open.
What were Kymera Therapeutics's Q1 2026 revenue and EPS?
Kymera Therapeutics reported revenue of $34.4M and eps of $-0.71 for Q1 2026.
Did Kymera Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $8.3M by $26.1M. EPS beat the consensus estimate of $-0.89 by $0.18.
How did Kymera Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 55.5% from $22.1M a year earlier and eps grew 13.4% from $-0.82.
Where can I find Kymera Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-193957) and the 10-Q periodic report (0001193125-26-193967) directly on SEC EDGAR. The filing index links above go to sec.gov.